Psoriasis is a chronic, inflammatory, immune-mediated skin disease affecting 1-3% of the adult population. It mainly involves the skin, nails, and joints. However, psoriasis can be associated with several comorbidities, including ocular complications. The most frequently reported pathologies are dry eyes syndrome, blepharitis, and uveitis. Being a systemic inflammatory disease, psoriasis also has the potential to directly affect the retina. It has been reported that ocular manifestations tend to appear much later than skin and joint involvement. Eye complications begin insidiously, and progress asymptomatically. This can lead to a decrease in the quality of life and even permanently compromised visual function if not treated properly. Thus, the present review aimed to present current pathological explanations between psoriasis and ocular manifestation, and to evaluate the prevalence of ocular changes in patients with psoriasis, in order to be diagnosed and managed appropriately.
Psoriasis is a chronic and complex disease that consists of characteristic cutaneous lesions and is frequently accompanied by systemic comorbidities caused by the chronic inflammatory state. The most common such comorbidities are hypertension, diabetes mellitus, dyslipidemia, inflammatory bowel diseases, depression, anxiety, neoplasia, and non-alcoholic fatty liver disease. Therefore, it is of utmost importance to simultaneously treat both psoriasis and the associated conditions with the best therapies available to improve patients’ life quality. Therefore, this review aims to evaluate the effects of biological therapies on both psoriasis and its comorbidities and also to highlight other future options.
